CVRx appoints John Landry CFO with 0.8% equity grant
CVRx, Inc. (CVRX) announced that its Board of Directors has appointed John Landry as Chief Financial Officer, succeeding Jared Oasheim.
Rhea-AI Filing Summary
CVRx, Inc. (CVRX) announced that its Board of Directors has appointed John Landry as Chief Financial Officer, succeeding Jared Oasheim. Landry will join on October 12, 2026 and assume CFO responsibilities after the company files its Form 10-Q for the quarter ending September 30, 2026, with Oasheim remaining during a transition period.
Landry brings over two decades of financial leadership in medical devices, including CFO roles at Nyxoah SA and Vapotherm, and prior experience at Medtronic and Salient Surgical Technologies. His compensation includes a $500,000 base salary, a 50% target cash incentive, and initial equity awards representing 0.80% of common shares, granted under the Nasdaq inducement grant exemption.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Base salary: $500,000 per year
Target cash incentive: 50% of base salary
Equity award size: 0.80% of base common shares
+4 more
7 metrics
Base salary
$500,000 per year
Initial annual base salary for John Landry as CVRx CFO
Target cash incentive
50% of base salary
Pro-rated target bonus for fiscal 2026 for John Landry
Equity award size
0.80% of base common shares
Initial equity awards for John Landry as a percentage of shares outstanding
Option to RSU ratio
1.5:1
Mix used to size stock options versus RSUs in Landry’s initial awards
Employment start date
October 12, 2026
Date John Landry will join CVRx
Quarter-end reference
September 30, 2026
Quarter-end after which Landry assumes CFO responsibilities, following Form 10-Q filing
Age of new CFO
54 years
Age of John Landry at the time of appointment as CFO
Key Terms
Nasdaq inducement grant exemption, restricted stock units, Form 10-Q, Emerging growth company, +2 more
6 terms
Nasdaq inducement grant exemption regulatory
"will be granted under the Nasdaq inducement grant exemption"
restricted stock units financial
"25% of restricted stock units (“RSUs”) that together represent"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Form 10-Q regulatory
"the day after the Company files its Form 10-Q for the quarter"
A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.
Emerging growth company regulatory
"Emerging growth company x"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Breakthrough Device designation medical
"Barostim received the FDA Breakthrough Device designation"
A breakthrough device designation is a regulatory program that gives promising medical devices for serious or life‑threatening conditions priority support and faster review from a health authority (e.g., the U.S. FDA). Think of it as a “fast lane” or VIP pass through development and review: it can shorten time to market, lower regulatory uncertainty, and boost a company’s commercial prospects — but it is not an approval by itself.
CE Mark approval medical
"holds CE Mark approval for heart failure and resistant hypertension"
CE mark approval is a declaration that a product meets European safety, health and performance requirements and may be placed on the market in the European Economic Area; for regulated items such as medical devices this follows required testing or a conformity assessment. Think of it as a passport or safety sticker that opens access to European customers; for investors it reduces regulatory roadblocks and can materially expand addressable market and revenue potential, though it is not a guarantee of commercial success.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who was appointed as the new CFO of CVRX and when will he start?
CVRx appointed John Landry as Chief Financial Officer. He will join the company on October 12, 2026 and assume the CFO role after CVRx files its Form 10-Q for the quarter ending September 30, 2026, following a transition period with outgoing CFO Jared Oasheim.
What is the compensation package for CVRX’s new CFO John Landry?
John Landry will receive an initial annual base salary of $500,000, a target cash incentive award of 50% of base salary (pro-rated for 2026), and initial equity awards (75% options, 25% RSUs) representing 0.80% of base common shares, plus certain bonus make-whole and travel reimbursements.
How large is the equity inducement grant for the new CVRX CFO?
The initial equity awards for John Landry will together represent 0.80% of CVRx’s base total common shares outstanding on his employment start date, using a 1.5:1 multiple of stock options to RSUs, and will be issued under the Nasdaq inducement grant exemption.
What is the transition plan from CVRX’s current CFO to John Landry?
Outgoing CFO Jared Oasheim, who previously announced his resignation, will remain with CVRx for a transition period. Landry joins on October 12, 2026 and assumes CFO duties the day after the company files its Form 10-Q for the quarter ending September 30, 2026.
What relevant experience does CVRX’s new CFO John Landry have?
John Landry has over two decades of medtech finance experience, including serving as CFO of Nyxoah SA, where he raised multiple capital rounds, and SVP and CFO of Vapotherm, Inc., where he led its IPO and built finance, investor relations and public company reporting functions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
